ANG Lifesciences India Limited (BOM:540694)
India · Delayed Price · Currency is INR 35.73
-0.21 (-0.58%)
At close: Jul 27, 2026
ANG Lifesciences India Ratios and Metrics
Market cap in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 24, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
| 473 | 297 | 589 | 993 | 2,432 | 445 | |
Market Cap Growth | 15.66% | -49.60% | -40.72% | -59.17% | 446.85% | 184.11% |
Enterprise Value | 1,229 | 1,112 | 1,243 | 1,668 | 3,307 | 632 |
Last Close Price | 36.19 | 22.72 | 45.08 | 76.05 | 187.68 | 34.27 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 24, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
PE Ratio | - | - | - | - | 6.03 | 6.33 |
PS Ratio | 0.55 | 0.32 | 0.40 | 0.45 | 0.69 | 0.29 |
PB Ratio | 0.80 | 0.46 | 0.77 | 1.15 | 2.90 | 1.07 |
P/TBV Ratio | 0.80 | 0.46 | 0.77 | 1.15 | 2.90 | 1.08 |
P/FCF Ratio | 16.75 | - | - | 6.23 | - | 9.08 |
P/OCF Ratio | 9.80 | - | - | 3.77 | 9.84 | 4.86 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 24, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
EV/Sales Ratio | 1.43 | 1.20 | 0.85 | 0.76 | 0.93 | 0.41 |
EV/EBITDA Ratio | - | - | 13.97 | 7.40 | 4.88 | 4.52 |
EV/EBIT Ratio | - | - | 90.16 | 12.39 | 5.35 | 4.99 |
EV/FCF Ratio | 43.55 | - | - | 10.47 | - | 12.89 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 24, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Debt / Equity Ratio | 1.52 | 1.30 | 0.96 | 0.82 | 0.92 | 1.04 |
Debt / EBITDA Ratio | - | - | 7.47 | 3.10 | 1.14 | 3.09 |
Debt / FCF Ratio | - | - | - | 4.44 | - | 8.81 |
Net Debt / Equity Ratio | 1.46 | 1.24 | 0.88 | 0.75 | 0.84 | 0.95 |
Net Debt / EBITDA Ratio | -21.04 | -41.76 | 7.54 | 2.87 | 1.04 | 2.81 |
Net Debt / FCF Ratio | - | -19.86 | -4.45 | 4.05 | -4.23 | 8.02 |
Asset Turnover | - | 0.39 | 0.56 | 0.77 | 1.63 | 1.30 |
Inventory Turnover | - | 1.17 | 1.98 | 3.53 | 8.11 | 7.11 |
Quick Ratio | - | 0.50 | 0.55 | 0.56 | 0.66 | 0.74 |
Current Ratio | - | 1.15 | 1.24 | 1.14 | 1.16 | 1.26 |
Return on Equity (ROE) | - | -17.70% | -12.48% | -0.31% | 64.33% | 18.46% |
Return on Assets (ROA) | - | -1.93% | 0.33% | 2.96% | 17.79% | 6.65% |
Return on Invested Capital (ROIC) | -5.44% | -5.09% | 0.94% | -0.88% | 39.67% | 13.23% |
Return on Capital Employed (ROCE) | - | -8.50% | 1.40% | 11.70% | 49.60% | 24.30% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 24, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Earnings Yield | -24.89% | -41.84% | -17.23% | -0.26% | 16.58% | 15.80% |
FCF Yield | 5.97% | -13.51% | -25.59% | 16.04% | -6.84% | 11.02% |
Dividend Yield | - | - | - | - | 0.43% | - |
Payout Ratio | - | - | - | - | 2.57% | - |
Buyback Yield / Dilution | -1.20% | - | -0.51% | -0.26% | - | - |
Total Shareholder Return | -1.20% | - | -0.51% | -0.26% | 0.43% | - |